Insider · CIK 0001650131
Peter Radovich
Files at MIRM (Mirum Pharmaceuticals, Inc.). First filing Jan 23, 2026, latest Mar 17, 2026.
In brief
Peter Radovich files SEC Form 4 as COO and president at MIRM (Mirum Pharmaceuticals, Inc.). Since Jan 23, 2026, Peter Radovich has reported 0 open-market buys worth $0 and 4 open-market sells worth $2.3M, the latest filed on Mar 17, 2026.
A track record needs three past buys with six months of prices behind them; Peter Radovich has 0, so none is measured yet.
The newest scored trade: sold $1.5M of MIRM on Mar 16, 2026, filed Mar 17, 2026, scored 55 (moderate). In the last 12 months: 0 buys worth $0 and 4 sells worth $2.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MIRM: Mirum Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Mirum Pharmaceuticals, Inc. | $1.5M 16,515 shares | -29% | +141% from low-15% from high | |
| 53Moderate | Mirum Pharmaceuticals, Inc. | $272k 2,631 shares | -11% | +170% from low0% from high | |
| 39Weak | Mirum Pharmaceuticals, Inc. | $302k 3,143 shares | -12% | +152% from low0% from high | |
| 37Weak | Mirum Pharmaceuticals, Inc. | $222k 2,382 shares | -10% | +150% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 17, 2026 | MIRM MIRUM PHARMACEUTICALS, INC. | 16,515 0.03% of outstanding | $1.5M | Mar 16, 2026 | $796k |
| Feb 2, 2026 | MIRM MIRUM PHARMACEUTICALS, INC. | 2,631 0.01% of outstanding | $273k | Feb 2, 2026 | $525k |
| Jan 28, 2026 | MIRM MIRUM PHARMACEUTICALS, INC. | 3,143 0.01% of outstanding | $305k | Jan 26, 2026 | $222k |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | 14,850 0.03% of outstanding | $676k | Mar 4, 2025 | $364k |
Transactions
Every row this insider has filed, 19 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +16,988 | $19.19 | $326k | 57,260 | Jun 8, 2026 |
| Jun 5, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Stock Option (right to buy)derivative | -16,988 | $0.00 | $0 | 48,012 | Jun 8, 2026 |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +7,220 | - | - | 33,787 | Mar 17, 2026 |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +23,000 | - | - | 56,787 | Mar 17, 2026 |
| Mar 16, 2026 | MIRM Mirum Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -16,515 | $91.98 | $1.5M | 40,272 | Mar 17, 2026 |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Performance Restricted Stock Unitsderivative | -7,220 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Performance Restricted Stock Unitsderivative | -23,000 | $0.00 | $0 | 11,500 | Mar 17, 2026 |
| Mar 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,912 | $15.87 | $94k | 26,567 | Mar 11, 2026 |
| Mar 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Stock Option (right to buy)derivative | -5,912 | $0.00 | $0 | 54,088 | Mar 11, 2026 |
| Feb 2, 2026 | MIRM Mirum Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,631 | $103.30 | $272k | 20,655 | Feb 3, 2026 |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +25,120 | $0.00 | $0 | 25,120 | Jan 30, 2026 |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +16,280 | $0.00 | $0 | 16,280 | Jan 30, 2026 |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | AGrant or award Performance Restricted Stock Unitsderivative | +34,500 | $0.00 | $0 | 34,500 | Jan 30, 2026 |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +5,750 | - | - | 26,429 | Jan 27, 2026 |
| Jan 26, 2026 | MIRM Mirum Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,143 | $96.19 | $302k | 23,286 | Jan 27, 2026 |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,750 | $0.00 | $0 | 5,750 | Jan 27, 2026 |
| Jan 21, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Common Stock | +4,167 | - | - | 23,061 | Jan 23, 2026 |
| Jan 22, 2026 | MIRM Mirum Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,382 | $93.33 | $222k | 20,679 | Jan 23, 2026 |
| Jan 21, 2026 | MIRM Mirum Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,167 | $0.00 | $0 | 8,333 | Jan 23, 2026 |
Questions about Peter Radovich
Answered from the filings on this page, as of the latest one.
Is Peter Radovich buying or selling?
In the last 12 months Peter Radovich reported 0 open-market buys worth $0 and 4 open-market sells worth $2.3M on SEC Form 4; the latest was sold $1.5M of MIRM on Mar 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Peter Radovich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Radovich has 0.
Where does Peter Radovich file Form 4?
Peter Radovich has filed Form 4 at MIRM (Mirum Pharmaceuticals, Inc.) as PRESIDENT AND COO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.